LENZ Stock Forecast & Price Target

LENZ Therapeutics is expected to experience continued growth over the coming years as the company's differentiated mechanism of action and the initial success of their VIZZ product will continue to drive increases in revenue. The recent increase in the company's sales team and their efforts to target top eye care professionals and utilize a DTC campaign featuring Sarah Jessica Parker will likely further boost sales and awareness of the product. While there are some risks involved, such as potential failure to secure funding or achieve maximum revenue estimates, the company's strong initial launch and ongoing commercial initiatives make it an attractive investment opportunity with a buy rating and a revised price target of $38 per share.

LENZ Therapeutics is in the late stages of developing and commercializing VIZZ, a once-daily eye drop that aims to improve near vision for up to 10 hours. However, the company's financials for 1Q26 showed lower revenues and higher expenses, resulting in a significant net loss. We remain on the lookout for how well VIZZ is performing in the market, especially compared to similar drugs like AbbVie's VUITY, and how the company's expansion plans outside of the US will affect its financials and market penetration. With VIZZ being in the early stages of its launch, it is crucial to see if the commercial efforts can gain momentum and if ECPs will routinely consider VIZZ as a potential option for presbyopia patients. Therefore, we are also interested in the company's ongoing efforts to expand its commercial infrastructure and engage with top prescribers.